Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
23.05
+0.11 (0.48%)
At close: Apr 10, 2026, 4:00 PM EDT
23.49
+0.44 (1.91%)
After-hours: Apr 10, 2026, 6:45 PM EDT
Alumis Employees
As of December 31, 2025, Alumis had 224 total employees, including 221 full-time and 3 part-time employees. The number of employees increased by 54 or 31.76% compared to the previous year.
Employees
224
Change
54
Growth
31.76%
Revenue / Employee
$107,366
Profits / Employee
-$1,086,272
Market Cap
2.93B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 224 | 54 | 31.76% | 221 | 3 |
| Sep 30, 2025 | 223 | 76 | 51.70% | 221 | 2 |
| Jun 30, 2025 | 227 | 97 | 74.62% | 225 | 2 |
| Mar 31, 2025 | 184 | 75 | 68.81% | 182 | 2 |
| Dec 31, 2024 | 170 | 61 | 55.96% | 168 | 2 |
| Sep 30, 2024 | 147 | 38 | 34.86% | 145 | 2 |
| Jun 30, 2024 | 130 | - | - | 128 | 2 |
| Mar 31, 2024 | 109 | - | - | 107 | 2 |
| Dec 31, 2023 | 109 | - | - | 107 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcus Biosciences | 601 |
| Travere Therapeutics | 497 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 258 |
| Vera Therapeutics | 249 |
| Soleno Therapeutics | 182 |
| Catalyst Pharmaceuticals | 182 |
ALMS News
- 13 days ago - Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis - GlobeNewsWire
- 22 days ago - Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements - GlobeNewsWire
- 23 days ago - Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 5 weeks ago - Alumis to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Alumis to Participate in Upcoming February Investor Conferences - GlobeNewsWire
- 3 months ago - Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 3 months ago - Alumis Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - Alumis Announces Proposed Public Offering of Common Stock - GlobeNewsWire